Propanc Biopharma, Inc.
NCM: PPCBLive Quote
About Propanc Biopharma, Inc.
Healthcare
Biotechnology
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
📊 Fundamental Analysis
Propanc Biopharma, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -1811.7%, which indicates that capital utilization is currently under pressure.
At a current price of $0.10, PPCB currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $0.10 - $11.00).
💰 Valuation Insight
PPCB trades at a 100.0% discount (PE: 0.00), which may represent a value opportunity given the sector average of 25.00.
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$3.14M
Trailing P/E
0.00
Forward P/E
--
Beta (5Y)
3.52
52W High
$11.00
52W Low
$0.10
Avg Volume
2.23M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App